Cantor Fitzgerald downgraded Seelos Therapeutics to Neutral from Overweight without a price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SEEL:
- Seelos (NASDAQ: SEEL) Tumbles as Phase 2 Trial Disappoints
- Seelos Therapeutics announces data from Phase II study of SLS-002
- Seelos Therapeutics files to sell 5M shares of common stock for holders
- Seelos Therapeutics options imply 10.2% move in share price post-earnings
- Seelos Therapeutics, Inc. (SEEL) Q2 Earnings Cheat Sheet